New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ From The Last 14 Days
Check below for free stories on CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
April 17, 2014
12:53 EDTWLP, UNH, AETOn The Fly: Midday Wrap
Subscribe for More Information
10:56 EDTUNHUnitedHealth backs FY14 EPS, revenue guidance
UnitedHealth earlier backed its FY14 EPS view of $5.40-$5.60, consensus $5.59, and its FY14 revenue view of $128B-$129B, consensus $128.94B.
10:51 EDTUNH, WLP, AET, HNT, HUMHealth insurers slide after UnitedHealth results, cautious comments
Shares of a number of health insurers are falling after the largest company in the sector, UnitedHealth (UNH), reported slightly higher than expected first quarter profit but lower than expected revenue. WHAT'S NEW: UnitedHealth's first quarter earnings per share came in at $1.10, versus the consensus outlook of $1.09. The insurer reported revenue of $31.71B, compared with the consensus outlook of $31.99B. Taxes levied by the Affordable Care Act and weak funding of Medicare Advantage by the government weighed on UnitedHealth's earnings, the company stated. Also pushing down the company's earnings was "a very expensive," new Hepatitis C therapy, UnitedHealth stated on its earnings conference call. Hepatitis C treatments cost UnitedHealth hundreds of millions of dollars in the first quarter, the company stated, though it also noted that demand for the treatments should drop going forward as initial pent-up demand for them starts to decline. The company indicated that it was looking to be reimbursed by states for the money it is spending on hepatitis vaccines for Medicaid patients. Meanwhile, UnitedHealth reiterated its fiscal 2014 EPS guidance of $5.40-$5.60 and its fiscal 2014 revenue guidance of $128B-$129B. PRICE ACTION: In mid-morning trading, UnitedHealth sank 3.7% to $75.31. Other health insurers also declined, with WellPoint (WLP) dropping 4% to $91.89, Aetna (AET) falling 3.3% to $67.54, Humana (HUM) declining 2.25% to $106.35, and Health Net (HNT) sliding 1% to $31.74.
08:00 EDTSTJSt. Jude Medical price target lowered to $47 from $51 at Canaccord
Subscribe for More Information
06:02 EDTUNHUnitedHealth:Q1 negatively impacted by ACA taxes, ACA provisions, sequestration
Subscribe for More Information
06:02 EDTUNHUnitedHealth reports Q1 Medical Care Ratio 82.5%
Reports Q1 Optum revenue $11.2B
06:01 EDTUNHUnitedHealth reports Q1 EPS $1.10, consensus $1.09
Subscribe for More Information
April 16, 2014
17:53 EDTMDTEdwards says not looking for complete ban of Medtronic valve, Bloomberg says
Subscribe for More Information
15:39 EDTSTJ, BSXBoston Scientific CRT-D approval neutral for St. Jude, says Wells Fargo
Subscribe for More Information
15:17 EDTUNHNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include General Electric (GE), consensus 32c; Philip Morris (PM), consensus $1.16; Schlumberger (SLB), consensus $1.20; PepsiCo (PEP), consensus 75c; Union Pacific (UNP), consensus $2.37; UnitedHealth (UNH), consensus $1.09; Honeywell (HON), consensus $1.26; Goldman Sachs (GS), consensus $3.44; du Pont (DD), consensus $1.59; Morgan Stanley (MS), consensus 60c; Danaher (DHR), consensus 80c; BlackRock (BLK), consensus $4.14; Blackstone (BX), consensus 55c; Chipotle Mexican Grill (CMG), consensus $2.86; Mattel (MAT), consensus 9c; Snap-on (SNA), consensus $1.54; AutoNation (AN), consensus 74c.
12:01 EDTHUMHumana, Dignity Health sign agreement
Subscribe for More Information
10:08 EDTUNH, HUM, WLP, AETUnitedHealth retreats after Citi cuts rating on shares
Subscribe for More Information
10:00 EDTCNCOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A10 Networks (ATEN) initiated with a Buy at BofA/Merrill... Actavis (ACT) initiated with a Buy at Sterne Agee... Allergan (AGN) initiated with a Buy at Sterne Agee... Autohome (ATHM) initiated with a Neutral at Credit Suisse... BitAuto (BITA) initiated with an Outperform at Credit Suisse... Centene (CNC) initiated with a Neutral at UBS... Endo International (ENDP) initiated with a Buy at Sterne Agee... FS Investment (FSIC) initiated with an Overweight at Evercore... Hertz (HTZ) initiated with a Buy at Gabelli... Hilton (HLT) initiated with a Hold at Jefferies... Hospira (HSP) initiated with a Neutral at Sterne Agee... ImmunoGen (IMGN) initiated with a Buy at Canaccord... Impax (IPXL) initiated with a Neutral at Sterne Agee... Imperva (IMPV) assumed with a Neutral at Wedbush... Ingredion (INGR) initiated with an Outperform at Credit Suisse... Laredo Petroleum (LPI) initiated with an Outperform at RW Baird... Lpath (LPTN) initiated with a Buy at Canaccord... MediWound (MDWD) initiated with an Outperform at Oppenheimer... Medivation (MDVN) initiated with a Hold at Canaccord... NPS Pharmaceuticals (NPSP) assumed with a Buy at Canaccord... Nimble Storage (NMBL) initiated with a Market Perform at Raymond James... Regeneron (REGN) initiated with a Buy at Canaccord... Salix (SLXP) initiated with a Buy at Sterne Agee... Sibanye Gold (SBGL) initiated with an Outperform at Imperial Capital... Teva (TEVA) initiated with a Neutral at Sterne Agee... Wipro (WIT) assumed with a Hold at Jefferies.
10:00 EDTUNHOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTSTJSt. Jude Medical falls 4.3%
Subscribe for More Information
09:27 EDTUNHUnitedHealth April volatility elevated at 48 into Q1 and outlook
UnitedHealth April call option implied volatility is at 48, June is at 22, September is at 21; compared to its 26-week average of 23 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 17.
09:01 EDTWLPWellPoint names Martin Silverstein as Chief Strategy Officer, effective April 28
WellPoint announced Martin Silverstein, M.D., has been named chief strategy officer, effective April 28. In this role, Dr. Silverstein will oversee WellPoint’s enterprise marketing, corporate development and strategy functions, and will be responsible for short and long-term strategic planning to ensure the company is maximizing the value of its assets and capturing growth across its geographies and businesses. Silverstein joins WellPoint from The Boston Consulting Group where he was a Senior Partner and Managing Director.
08:33 EDTSTJSt. Jude Medical sees total Q2 CRM sales $705M-$735M
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical sees FY14 consolidated adjusted EPS $3.95-$4.00
Subscribe for More Information
07:33 EDTSTJSt. Jude Medical sees Q2 consolidated adjusted EPS 99c-$1.01, consensus $1.00
Sees Q2 revenue $1.38B-$1.46B, consensus $1.44B.
07:31 EDTSTJSt. Jude Medical reports Q1 adjusted EPS 96c, consensus 95c
Subscribe for More Information
05:39 EDTUNHUnitedHealth downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
05:34 EDTCNCCentene initiated with a Neutral at UBS
Target $62.
April 15, 2014
16:47 EDTBSXBoston Scientific announces FDA approval for defibrillators
Subscribe for More Information
15:19 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
11:53 EDTBSXVascular Solutions: Injunction against Boston Scientific's Guidezilla vacated
Subscribe for More Information
09:23 EDTSTJ, BSXBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
06:32 EDTWLP, HS, WCG, AGP, CI, UNH, MOH, HUM, CNC, HNT, AETPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
16:24 EDTMDTOn The Fly: Closing Wrap
Subscribe for More Information
12:26 EDTMDTOn The Fly: Midday Wrap
Subscribe for More Information
10:51 EDTMDTEdwards up after court limits sale of Medtronic's CoreValve in U.S.
Subscribe for More Information
10:23 EDTWCGHigh option volume stocks: CCL WCG LSI INTU IACI
Subscribe for More Information
10:02 EDTMDTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:02 EDTBSXOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
09:00 EDTMDTMedtronic falls 5.4%
Medtronic is down 5.4%, or $3.20, to $56.00
08:59 EDTMDTOn The Fly: Pre-market Movers
Subscribe for More Information
07:39 EDTMDTEdwards Lifesciences upgraded to Buy from Fair Value at CRT Capital
Subscribe for More Information
06:44 EDTBSXBoston Scientific upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Boston Scientific to Buy from Neutral. The firm upgraded shares given increased confidence in the pipeline, opportunities to increase margin, valuation, and expectations the FDA will approve the LAA product this year. Price target raised to $16.
06:22 EDTMDTMedtronic downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:21 EDTMDTEdwards Lifesciences upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
06:18 EDTBSXBoston Scientific upgraded to Buy from Neutral at BofA/Merrill
Price target is $16.
April 13, 2014
15:10 EDTMDTMedtronic says CoreValve ruling has no impact outside U.S.
Subscribe for More Information
April 12, 2014
19:50 EDTMDTEdwards says court limits sale of Medtronic CoreValve system in U.S.
Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the United States. The court ordered the injunction to go into effect in seven business days. The hearing related to a federal jury decision in 2010 that CoreValve willfully infringes Edwards' U.S. Andersen transcatheter aortic valve replacement patent. At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. There is a large body of evidence demonstrating the safety and performance of the Edwards SAPIEN valves, and the company remains committed to ensuring patients have appropriate access to transcatheter therapy. This case was initiated by Edwards in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In Nov. 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision; in Oct. 2013, the U.S. Supreme Court declined to hear Medtronic's appeal. The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
April 11, 2014
10:05 EDTAETAetna, Tenet form accountable care collaboration in San Antonio
Aetna (AET), Tenet’s (THC) Baptist Health System and HealthTexas Medical Group announced an accountable care collaboration and the introduction of the Aetna Whole Health product in the San Antonio area. The health plans, designed for fully insured customers with employees who live or work in Bexar, Guadalupe, Comal and Kendall counties, will be available on July 1.
April 10, 2014
19:10 EDTMDTMedtronic confirms FDA approval for expanded indications
Subscribe for More Information
18:34 EDTBSXBoston Scientific enrolls first patient in registry for evaluating Vercise DBS
Subscribe for More Information
16:32 EDTMDTMedtronic gets FDA approval for revised labeling application
The U.S. FDA approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators, expanding the indication for use to patients with atrioventricular block and less severe heart failure. The FDA previously approved these devices for patients with more severe heart failure as evaluated by their physician using specific criteria. The new approved use includes patients with less severe heart failure, but who are already indicated to receive RV pacing. With the new indication, these patients will be eligible to receive a device that will pace both sides of their heart instead of just the right. Reference Link
15:56 EDTWLP, WCGWellCare rumored to be takeover target, Betaville blog says
Wellcare (WCG) which has previously been speculated as a takeover target by analysts, is being studied as a target by Wellpoint (WLP), according to the Betaville blog, which cites sources familiar with the matter. Shares of WellCare, which have been lower throughout the session, briefly spiked following the blog post, but have returned to negative territory in late afternoon trading. Reference Link
15:52 EDTWCGWellCare rumored to be takeover target, Betaville blog says
Subscribe for More Information
April 8, 2014
11:02 EDTHUMHumana now sees 2015 CMS Medicare Advantage funding decline of 3%
Subscribe for More Information
10:18 EDTHNT, AET, HUM, WCG, WLP, CI, UNHCMS says Medicare Advantage reimbursement to rise in 2015
Subscribe for More Information
09:23 EDTAET, WCG, UNH, MOH, CI, HUM, CNC, HNT, WLPLeerink views final rates as favorable for MA plans
Subscribe for More Information
07:26 EDTMDTElsevier Business Intelligence to hold a conference
Subscribe for More Information
April 7, 2014
19:13 EDTAET, MOH, CNC, HUM, HNT, WLP, HS, UNH, AGP, WCG, CICMS issues 2015 rate announcement for Medicare Advantage and Part D programs
Subscribe for More Information
18:01 EDTBSXBoston Scientific gets FDA, CE Mark clearance for Expect Slimline Needle
Boston Scientific announced it has received clearance from the U.S. FDA and CE Mark approval in Europe for the Expect Slimline Needle, which is now globally available for Endoscopic Ultrasound-Fine Needle Aspiration procedures. The Expect Slimline Needle is on contract with four leading group purchasing organizations.
10:02 EDTCICigna announces first collaborative care program in South Florida
Subscribe for More Information
07:58 EDTMDTMedtronic data positive for C.R. Bard, says Barclays
Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.
07:38 EDTMDTMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use